Individualized Telemedical Assistance for Lifestyle Modification in the Treatment of Obesity and Cardiometabolic Risk Prevention

N/ACompletedNCT01919372

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau183 enrolled

Overview

This project is based on the contribution that could offer a technological system for a continuous monitoring, individualized treatment of obesity and prevention of cardiometabolic complications in high risk population. The main objective of PREDIRCAM study is to evaluate the benefits obtained with the use in high cardiometabolic risk individuals of a telemedical platform integrating applications for monitoring and providing recommendations to improve lifestyle habits (diet and physical activity) in a healthier way. The study population are obese subjects (type I or II) aged between 25 and 65 years with a 12 month follow-up. In this population it will be analysed the cost-effectiveness of a telemedic assistance with a technological system and its ability to modify lifestyle habits, reduce weight and cardiovascular risk associated parameters. Previously to the clinical implementation, a pilot study for testing the telemedical system will be made. Efficacy and security variables will be evaluated along the study.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

183

Conditions

Obesity Type I and II

Interventions

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: Preclinical Phase: 1\. People over 18 years with or without obesity and with ability for technology management Clinical Phase: 1. People between 18 and 65 years. 2. Obesity defined as a body mass index (BMI) greater than or equal to 30 kg/m2: 1. Grade I or II without sleep apnea syndrome and ischemic heart disease 2. Absence of metabolic processes (dyslipidemia) or associated hypertension requiring drug treatment at the time of inclusion in the study. 3. People with ability for technology management Exclusion Criteria: Preclinical Phase: 1\. Serious illness and / or disabling Clinical Phase: 1. Diabetes defining according to American Diabetes Association (ADA) criteria. 2. Subjects with moderate to severe active disease at the time of inclusion in the study protocol 3. Impaired glucose metabolism related diseases associated with diabetes mellitus or drugs interfering carbohydrate metabolism. 4. Cardiovascular disease 5. Dyslipidemia or hypertension requiring drug treatment. 6. Alcohol consumption 7. Pregnancy 8. Serious illness and / or disabling

Outcomes

Primary Outcomes

Weight loss

Time frame: 1 year

Secondary Outcomes

Cardiometabolic risk prevention

We will measure different parameters related to cardiovascular risk, such as adiponectine, tumour necrosis factor, Homeostasis Model Assessment, etc.at the beginning and at the end of the study